# Reactivity Everywhere! Where do you go?

#### Our Mission:

To provide blood and support services that meet the needs of patients, donors, physicians and hospitals.



### Case 1

- 3/3 patient admitted to hospital for venous stress due to Cellulitis
- Hgb 8.1
- WBC 8.9
- Not transfused in last 3 months





# March 6 Sample Arrives in IRL



- Hgb 6.0
- WBC 11.55
- Hospital reports possible anti-e or anti-f
- A negative
- DAT Positive
  - 3+ IgG, complement negative
- Not recently transfused
  - First impression is this sounds like an auto antibody



# Why we're thinking WARM Auto

DAT is positive, but no recent transfusions

- Patient is Rh Negative
  - Most likely e+

Hospital is reporting a possible anti-e



#### LISS Panel

### Consistent with Warm Auto Antibody

Fyb

Jka

Jkb

+

+

+

S

Ν

**Results** 

IAT

LISS

Consistent	VVICII	vvari	ппди	to Antibo	Juy
Rh	Kell	Duffy	Kidd	MNSs	Test

Fy<sup>a</sup>

Ε

+

С

+

+

+

AC

f

+

+

e

K

+

k

### Ficin Treated Red Cell Panel

			F	Rh			K	Kell		Duffy		Kidd		MNSs				Test Results	
	D	С	С	E	e	f	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jka	Jk <sup>b</sup>	М	N	S	S	30′ 37	IAT	
1	+	+	0	+	0	0	0	+	+	+	+	+	+	0	+	0	0	0	
3	+	0	+	+	0	0	0	+	0	+	+	+	0	+	0	+	0	0	
7	0	0	+	0	+	+	+	+	0	+	0	+	+	+	0	+	1+	2+	
9	0	0	+	0	+	+	0	+	0	+	+	0	+	+	+	0	1+	2+	
10	+	+	0	0	+	0	0	+	+	+	0	+	0	+	0	+	1+	<b>M</b> +	

# Anti-e detected could still be Warm Auto Antibody

# Negative Acid Eluate!

			R	h			K	ell	Du	iffy		da		MNS	S		Test Results
	D	С	С	Е	e	f	K <	k		Fy <sup>b</sup>	Jk <sup>a</sup> (	√k <sup>b</sup>	M	N	S	S	Peg IAT
1	+	+	0	+	+	0	0	+	0	+		+	0	+	0	+	0
2	+	+	0	0	+~	0		+	+	3/	0	)+	+	+	+	0	0
3	+	0	+	+		0	0	+	+			+	+	0	+	+	0
4	+	0	+		+	+	0	<b>5</b> 2		0	+	+	+	0	0	0	0
5	0	+	+		+	+	0	171	3	+	0	+	+	+	+	+	0
6	0	0	+	+	+	+	9		+	+	+	0	+	0	+	0	0
7	0	0	+	0	+	+	+	+	0	+	+	0	+	0	0	+	0
8	0	0	+	0	+	+	0	+	+	0	+	0	0	+	0	+	0
9	0	0	+	0	+	+	0	+	0	+	+	+	+	0	0	+	0
10	+	+	0	0	+	0	+	+	0	+	0	+	+	+	+	+	0
11	+	0	+	+	+	+	0	+	+	0	+	+	+	0	+	+	0
EGA	Trea	ted A	uto Co	ontro	l												0
i																	

### Time for the Ether

#### **Potential Health Effects**

#### Inhalation:

#### Irritant. General anesthesia by inhalation can occur.

Continued exposure may lead to respiratory failure or death.

Early symptoms include irritation of nose and throat, vomiting, and irregular respiration, followed by dizziness,

drowsiness, and unconsciousness.

#### **Ingestion:**

Irritating to the mucous membranes. Ingestion of 1 or 2 ounces may be fatal. Because of volatility the stomach

becomes distended, which may cause belching. Other symptoms can include vomiting, unconsciousness, and

#### coma. Skin Contact:

Irritating to the skin and mucous membranes by drying effect. Can cause dermatitis on prolonged exposure. May be absorbed through skin.

#### **Eve Contact:**

May cause irritation, redness and pain. Prolonged exposures to high concentrations of vapor can cause eye damage.

#### **Chronic Exposure:**

Repeated exposures may be habit forming. Prolonged exposures may result in headache, drowsiness, excitation,

and psychic disturbances. Teratogenic effects are possible.

#### **Aggravation of Pre-existing Conditions:**

Persons with pre-existing skin disorders or eye problems or impaired liver, kidney or respiratory function may be more susceptible to the effects of this substance. Alcoholic beverage con

Ether Eluate negative

Now everyone is dizzy

Screening Cell	Peg IAT
I	0
II	0
III	0





# Discussion What we Know

- DAT Postive IgG
- LISS negative
- Anti-e in FICIN
- Eluate negative (Acid and Ether)

#### What we need to know

- 1) Why is the DAT Positive?
  - Requested Drug List to be faxed to IRL
- 2) What is the nature of the anti-e?
  - Auto or allo?



## Anti-e detected in PEG

		Rh					Kell Duffy		Kidd		MNSs				Test Results		
	D	С	С	E	e	f	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jka	Jk <sup>b</sup>	М	N	S	S	Peg IAT
1	+	+	0	+	+	0	0	+	0	+	+	+	0	+	0	+	M+
2	+	+	0	0	+	0	0	+	+	0	0	+	+	+	+	0	1+
3	+	0	+	+	0	0	0	+	+	+	0	+	+	0	+	+	0
4	+	0	+	0	+	+	0	+	0	0	+	+	+	0	0	0	2+
5	0	+	+	0	+	+	0	+	0	+	0	+	+	+	+	+	2+
6	0	0	+	+	+	+	0	+	+	+	+	0	+	0	+	0	1+
7	0	0	+	0	+	+	+	+	0	+	+	0	+	0	0	+	1+
8	0	0	+	0	+	+	0	+	+	0	+	0	0	+	0	+	2+
9	0	0	+	0	+	+	0	+	0	+	+	+	+	0	0	+	2+
10	+	+	0	0	+	0	+	+	0	+	0	+	+	+	+	+	M+
11	+	0	+	+	+	+	0	+	+	0	+	+	+	0	+	+	M+

# Rule Out Panel all other common antibodies

			R	h			Ke	ell	Du	ffy	Ki	dd		MNS	S		Test Results
	D	С	С	E	е	f	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	M	N	S	S	Peg IAT
1	+	0	+	+	0	0	0	+	0	+	+	0	+	0	+	0	0
2	+	0	+	+	0	0	0	+	+	0	0	+	0	+	+	+	0
3	+	0	+	+	0	0	+	+	0	+	0	+	+	0	0	+	0
4	+	0	+	+	0	0	0	+	0	+	+	+	0	+	0	+	0
5	+	W	+	+	0	0	+	+	0	+	+	0	+	0	0	+	0
6	+	W	+	+	0	0	0	+	+	+	0	+	0	+	+	0	0
7	+	+	0	+	0	0	0	+	+	0	+	+	+	+	0	+	0
8	+	+	0	+	0		0	+	+	0	+	+	0	+	0	+	0

# Patient Phenotype rr, K- Fy(a+b-) Jk(a-b+) S- s+

- Some e+ patients lack e epitopes
- Can make a clinically significant anti-e
- Would require enegative blood





## Ho of Lw Ints to transfuse

They atch units

D-, C-, E-,e+ , K- , Fy(b-) Jk(a-), S-

2 choices

1. Send phenotypically matched (e+) nonreactive th LISS

Risks transfusion reaction due to e

z. Sent e- units that are not phenotypically matched nonreactive in PEG

• Exportent to E ant 1; not h tal's pre ence



## Drug List has arrived

- Aspirin
- Balsm-Trypis-Caster Oil
- Famotidine
- Heparin
- Hydralazine
- Insulin
- Nystatin
- Piperacillin/Tazobactum
- Pravastatin
- Sodium Chloride
- Acetaminophen

- Alum-Magnisium Hydroxide-Simeth
- Diazepam
- Docusate Sodium
- Fentanyl Citrate
- Hydrocodine
- Ondansetron HCL
- Polyethylene
- Zolpidem Tartrate
- Vancomycin



APPENDIX 17-1 Drugs Associated with a Po	sitive DAT an	d/or Immune H	lemolytic Anem	ia	APPENDIX 17-1 Drugs Associated with a Positive DAT and/or Immune Hemolytic Anemia (Continued)							
Drug		Method o	f Detection		Drug		Method o	f Detection	PHI PROMETER CONTRACTOR CONTRACTO			
Aceclofenac			+Drug	,	Cimetidine		DT	+Drug				
Acetaminophen			+ Drug		Ciprofloxacin	The state of the s		+Drug				
Acyclovir		DT			Cisplatin		DT		NIPA			
Aminopyrine		DT			Cladribine	AA	, , , , , , , , , , , , , , , , , , , ,					
Amoxicillin		DT	·····		Clavulanate				NIPA			
Amphotericin B			+ Drug		- Cyanidanol	AA	DT	+ Drug				
Ampicillin		DT	+ Drug		- Cyclofenil	AA		+ Drug				
Antazoline			+ Drug		- Cyclosporin		DT					
Azapropazone	AA	DT			Diclofenac	AA	DT	+ Drug				
Butizide		······································	+ Drug		Diethylstilbestrol			+ Drug				
Carbimazole	AA	DT	+ Drug		Diglycoaldehyde				NIPA			
Carboplatin	AA	DT	+ Drug	Proposition and an area of	_ Dipyrone		DT	+ Drug				
Carbromal		DT	. 5.09		Erythromycin		DT					
Cefamandole		DT	· · · · · · · · · · · · · · · · · · ·		Etodolac			+ Drug				
Cefazolin		DT			_ Fenoprofen	AA		+ Drug				
Cefixime		DT	+ Drug		_ Fluconazole		DT	+ Drug				
Cefotaxime		DT	+ Drug		Fludarabine	AA						
Cefotetan	AA	DT	+ Drug	NIPA	Fluorescein		DT	+ Drug				
Cefoxitin	AA	DT		NIFA	Fluorouracil			+ Drug				
Ceftazidime			+ Drug		Furosemide			+ Drug				
	AA	DT	+ Drug		Hydralizine	APPA APPA APPA APPA APPA APPA APPA APP	DT	i i				
Ceftizoxime		DT	+ Drug		Hydrochlorothiazide		DT	+ Drug				
Ceftriaxone			+ Drug		Hydrocortisone		DT	+ Drug				
Cefuroxime		DT			9-Hydroxy-methyl-ellipticinium			+ Drug				
Cephalexin		DT			lbuprofen			+Drug				
Cephalothin		DT	+ Drug	NIPA	Imatinib mesylate		DT					
Chloramphenicol	AA	DT			Insulin		DT					
Chlorinated hydrocarbons	AA	DT	+ Drug		Isoniazid		DT	+ Drug				
Chlorpromazine	AA		+ Drug		Levodopa	AA						
Chlorpropamide		The state of the s	+ Drug		Levofloxacin		DT	+Drug				
				(Continue)	Mefenamic acid	AA						

# Drugs that cause positive DATs and/or DIHA

- Hydralazine
- Acetaminophen
- Insulin
- Vancomycin
- Piperacillin





# Rh (D,E,c,E,e)

Catechin, diclofenac, glafenin, hydrochlorothiaide, ibuprofen, moxalactam, nomifensin, piperacillin, quinine, rifampin, streptomycin, sulindac, tolmetin

Chlorpheniramine, fluorouracil, Isopaque, nitrofurantoin, nomifensine, rifampin, thiopental

Р

Kell

Lutheran

Kidd

**MNS** 

Н

Elliptinim, melumine iothalamate, nomifensine

Glafenine, trimethoprim

Elliptinium, rifampin

Chlorpropamide

Streptomycin

Sulfamethoxazole


# How to distinguish between anti-e or Piperacillin?

- Perform a drug study?
  - Result won't be as helpful as you might think...
  - Study by ARC showed that when testing with drug coated cells – 91% of their donors already have piperacillin antibody!



# Test Panel Drug Adsorption

Neat Plasma	Drug coated RBC's	Uncoated RBC's
15 ' 22C	1+	0
30′ 37C	0	0
IAT	M+	0





# How to distinguish between anti-e or Piperacillin

- Perform a drug study?
  - Result won't be as helpful as you might thing...
  - 1. Study by ARC showed that when testing with drug coated cells 91% of their donor already have piperacillin antibody!
  - 2. "Immune complex" method recommended method for testing for piperacillin antibodies requires combination of drug and plasma (1:1)



# Test Panel "Immune Complex"

		e+ cell		Ficin tested e+ cell				
	30′ 22C	30′ 37C	IAT	30' 22C	30′ 37C	IAT		
Plasma + drug	2+	2+	2+	4+	4+	4+		
Plasma + PBS	0	0	0	0	0	0		
Drug + PBS	0	0	0	0	0	0		
Eluate + Drug	0	0	1+	1+	2+	2+		
Eluate + PBS	0	0	0	0	0	0		



# How to distinguish between anti-e or Piperacillin

- Perform a drug study?
  - Result won't be as helpful as you might thing...
  - Study by ARC showed that when testing with drug coated cells – 91% of their donor already have piperacillin antibody!
  - 2. Immune complex method recommended method for testing for piperacillin antibodies requires combination of drug and plasma (1:1)
    - » Sample we have already has piperacillin in it and we know that it's positive
  - 3. Could test the eluate and drug against cells
    - Piperacillin antibodies do not always react in the eluate
  - 4. Drug study wasn't ordered (good)
    - Time consuming, expensive, results vary, wouldn't learn anything new



# Requested a sample before drug was administered

Summary of the results

**NEGATIVE!!!!!** 

**NEGATIVE!!!!!** 

**NEGATIVE!!!!!** 



## Summary of results



**Panel** 



# Negative

# Negative


Sent 2 phenotypically matched units nonreactive at LISS IAT

– D-, C-, E- , K- , Fy(b-) Jk(a-), S-




### Time Line

Hgb (12.0-15.0)



### Need for antibiotics





### Data from IRL last 19 months

Positive DAT's	Negative Eluate	Patient on drug known to cause positive DAT	Cases where drug was suspected of hemolysis
527	55	26	3


<1% positive DAT's suspected to cause DIHA

#### **VERY RARE**



### Data from IRL

**Total** 





### Conclusion

- In our case study, we recognized that the reactivity we saw was most likely drug related and consistent with Piperacillin antibody
- The clinicians used that information along with other lab data and clinical evaluation to discontinue the piperacillin treatment and to switch to another antibiotic
- This saved the patient's life
- Important for blood bankers to recognize this phenomenon



## **Transition Slide**





# The Case of the Cold Nasty Sample Arrives in IRL

- 62 year old
- Female
- AB Positive
- History of Esophageal Varices
- Hgb 8.1
- Last transfused 3 RBC's 10 days prior
- Hospital reports history of cold nonspecific reactivity and hospital has been giving least incompatible
- Sent for antibody ID and units



n after washing

S

0

+

+

+

+

0

S

+

Ν

0

+

0

+

0

0

+

 $Jk^{\text{b}}$ 

+

0

+

+

+

+

+

0

0

0

M

+

+

+

0

+

+

+

+

+

Jka

0

+

+

0

0

+

0

+

+

5 '

**RT** 

2+s

3+

3+

3+

3+

3+

2+s

3+

3+

3+

3+

0

Peg

IAT

@

@

@

@

@

@

@

@

@

@

@

0

Very	strong	reactiv	ity a	t 22C
			@ =	agglutination

Leb

+

0

0

0

+

0

0

+

0

0

+

 $P_1$ 

+

+

+

+

0

0

+

+

Rh	Kell	Duffy	Lewis	Р	Kidd	MNSs	Test

Lea

0

0

+

+

0

0

+

0

+

+

0

Rh	Kell	Duffy	Lewis	Р	Kidd	MNSs	Re

Fy<sup>b</sup>

+

0

+

0

+

+

0

+

+

+

f

+

+

+

0

0

0

0

0

0

0

K

0

+

0

0

0

0

0

0

0

+

0

k

+

+

Fy<sup>a</sup>

0

+

0

+

0

0

+

0

+

+

+

D

0

0

0

+

+

0

1

3

4

5

6

8

9

10

11

C

0

0

0

0

0

0

+

+

Ε

0

0

0

+

+

0

0

+

0

0

C

+

+

+

+

0

0

0

**Auto Control** 

e

+

+

+

0

0

0

+

+

+

+

### What could this be...

Lewis, P1, and M are out

- High incidence Cold antibody?
  - Lets start there...











0

+

0

+

+

0

+

0

+

+

+

+

+

+

+

+

0

0

+

+

0

+

+

0

+

+

+

0

0

0

0

+

3+

3+

3+

3+

0

3+

+

+

+

+

+

0

+

+

+

@

@

@

@

@

1+w

@

2

3

4

5

6

7

8

0

0

+

Ge -2 -3

Ge -1 -2 -3

Vel-

Vel-

Tj (a-)

Group O

Tj (a-)

Group A

0

0

0

0

0

+

+

+

0

0

+

+

+

0

+

0

0

+

+

+

0

0

0

+

+

+

+

0

0

0

0

0

+

0

0

0

0

0

0

+

+

+

+

+

+

+

+

0

+

0

0

+

0

## Could it really be? Anti-Tja

@ = agglutination after washing

	Rare Factor			l	Rh			Ke	ell	Du	ffy	Ki	dd		MN	ISs			est ults
		D	С	С	E	e	f	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jk <sup>a</sup>	Jkb	M	N	S	S	5 ' RT	PEG IAT
1	Tj(a-)	+	+	+	0	+		0	+	0	+	+	+	+	0	0	+	<b>3+</b> <sup>s</sup>	@
2	Tj(a-)	+	+	+	0	+		0	+	+	+	+	0	0	+	0	+	3+	@
3	Tj(a-)	+	+ 0 +			0		0 +		+	0	+	0	0	+	0	+	3+	@

Nope – Too good to be true – Keep hunting





3

0

0

0

0

0

0

0

0

0

0

+


+

+

+

+

# Time for some Ficin



3+

@

1+w

@

0

0

+

+

Ficin w	ill des	stroy M,	N, S, s	, Fy <sup>a</sup> , Fy <sup>b</sup>	
Rh	Kell	Duffy	Kidd	MNSs	Test Results
					30 ' IAT 37C

	D	С	С	E	e	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	M	N	S	S	30 ' 37C	IAT
1	+	+	0	+	+	0	+	0	+	+	0	+	+	+	+	3+	@

	D	С	С	Е	е	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	М	N	S	S		
1	+	+	0	+	+	0	+	0	+	+	0	+	+	+	+	3+	@
_				_					0		0					•	_

	D	С	С	E	е	K	k	Fy <sup>a</sup>	Fy <sup>D</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	M	N	S	S		
																3+	
2	+	+	+	0	+	+	+	+	0	+	0	+	+	+	+	3+	@

																3+	
2	+	+	+	0	+	+	+	+	0	+	0	+	+	+	+	3+	@

+

0

0

0

0

## 2 negative cells

What do our 2 negative cells have in common?

5 min 22C

1) R1R1, K-, Fy(b-), N-, S-

Ficin 30' 37C 2) R1R1, K-, Fy(b-), N- S-






## Patient Phenotype


Microhematocrit cell separation

R1R1, K-, Fy(a+b+), Jk(a+b+) M+, N-, S-, s+

#### Patient can make:

- Anti-E
- Anti-c
- Anti-K
- Anti-N
- Anti-S









## Super Panel

			Rh			Ke	ell	Du	ffy	Ki	dd		MN	Ss		Test R	esults
	D	С	С	E	е	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jka	Jkb	М	N	S	S	5 '22C	IAT
1	+	+	0	0	+	0	+	0	+	+	0	+	0	0	+	0	1+
2	+	+	0	0	+	0	+	0	+	0	+	+	0	0	+	0	1+
3	+	+	0	0	+	0	+	+	0	+	0	+	0	0	+	0	1+
4	+	+	0	0	+	+	+	+	0	0	+	0	+	0	+	0	1+
5	+	+	0	0	+	+	+	0	+	0	+	0	+	0	+	0	1+
6	+	0	0	0	0	0	+	0	+	+	+	+	0	+	0	2+	@
7	+	+	0	0	+	0	+	+	0	+	+	+	0	+	0	2+	@
8	+	+	0	+	+	0	+	0	+	0	+	+	+	0	+	3+	@
9	+	+	0	+	+	0	+	+	+	+	+	+	0	0	+	3+	@
10	+	0	+	0	+	0	+	+	0	+	0	+	0	0	+	2+	@
11	0	0	+	0	+	0	+	0	0	+	+	+	0	0	+	2+	@

- All reacting at 22C and all agglutinating after washing
- Still something reacting at IAT 1+ even with antigen matched cells



### What we've identified at 22C

- Anti-E
- Clinically significant
  - Anti-c
- Clinically significant
  - Anti-S
- Clinically significant



## What we have yet to identify...

- 1+ reactivity at IAT
  - Even with phenotypically matched cells

- Hospital has reported a history of Cold Reactive Autoantibody
  - The weak reactivity at IAT is consistent with a cold
  - Need to prove that's what it is



	D	С	С	E	е	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	М	N	S	S	5 '22C	IAT	30 min 4C	PEG Prewarm
1	+	+	0	0	+	0	+	0	+	+	0	+	0	0	+	0	1+	4+	0
2	+	+	0	0	+	0	+	0	+	0	+	+	0	0	+	0	1+	4+	0
3	+	+	0	0	+	0	+	+	0	+	0	+	0	0	+	0	1+	4+	0
4	+	+	0	0	+	+	+	+	0	0	+	0	+	0	+	0	1+	4+	0
5	+	+	0	0	+	+	+	0	+	0	+	0	+	0	+	0	1+	4+	0
6	+	0	0	0	0	0	+	0	+	+	+	+	0	+	0	2+	@		2+
7	+	+	0	0	+	0	+	+	0	+	+	+	0	+	0	2+	@		2+
8	+	+	0	+	+	0	+	0	+	0	+	+	+	0	+	3+	@		3+
9	+	+	0	+	+	0	+	+	+	+	+	+	0	0	+	3+	@		3+
10	+	0	+	0	+	0	+	+	0	+	0	+	0	0	+	2+	@		3+
11	0	0	+	0	+	0	+	0	0	+	+	+	0	0	+	2+	@		3+
A	۱	to	Co	nt	rol													4+	0
	Community Blood Center Save a Life. Right Here, Right Now.																		

Kidd

Rh

Kell

Duffy

**Test Results** 

### Conclusion

- Identified 3 clinically significant antibodies
  - Anti-E, anti-c, and anti-S
  - All reacted strongly at 22C
  - All are clinically significant
- Also identified a cold reactive auto antibody that was circumvented by prewarmed testing
- Patient requires E-, c-, S- units nonreactive with the prewarmed plasma



#### Discussion

- Just because it reacts at 22C doesn't mean it can be ignored!!!
- Hospital reported history of cold antibody and had been giving least incompatible....!
- Possible that these are newly forming antibodies
  - Strongly reactive at 22C because they are still in IgM phase



### References

- Reid, M., & Lomas-Francis, C. (2004) The Blood Group Antigen Facts Book
   (2<sup>nd</sup> edition) London: Academic Press.
- Roback, J. (2011). Technical Manual (17<sup>th</sup> ed.). Bethesda, MD: AABB.
- Arndt, Pat., "Drug-Induced Hemolytic Anemia The Last 30 years of Changes. AABB Annual Meeting. Boston, Massachusetts. 10-06-2012.









